Cipher Pharmaceuticals Inc. (TSE:CPH - Get Free Report) NASDAQ: CPHR Director Harold Morton Wolkin sold 3,500 shares of Cipher Pharmaceuticals stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of C$13.49, for a total transaction of C$47,215.00.
Cipher Pharmaceuticals Stock Performance
CPH stock traded down C$0.33 during trading on Friday, hitting C$12.65. 15,822 shares of the company traded hands, compared to its average volume of 35,752. The company has a debt-to-equity ratio of 41.22, a current ratio of 2.00 and a quick ratio of 2.67. The company has a market cap of C$227.11 million, a PE ratio of 13.97 and a beta of 1.20. The stock's 50-day simple moving average is C$12.81 and its 200 day simple moving average is C$14.33. Cipher Pharmaceuticals Inc. has a 1 year low of C$7.90 and a 1 year high of C$19.69.
Cipher Pharmaceuticals Company Profile
(
Get Free Report)
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company's geographical segments include Canada and the United States.
Featured Articles
Before you consider Cipher Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cipher Pharmaceuticals wasn't on the list.
While Cipher Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
